Globally, there are approximately 100 mucosal vaccines against SARS-CoV-2 in development14, and preclinical studies have shown that nasally delivered vaccines targeting the Wuhan-1 S protein induce mucosal immunity and protect against infection by strains from early in the pandemic15–21. Here, PROS1 is linked to infection.